Immunoregulation and antidepressant effect of ketamine

Area of Science:

• Neuroscience
• Immunology
• Psychiatry

Background:

• Major depressive disorder (MDD) presents a significant global health burden.
• Current antidepressants targeting monoamine neurotransmitters exhibit limited efficacy, with high relapse rates.
• Ketamine, a glutamate N-methyl-D-aspartate receptor (NMDAR) antagonist, demonstrates potent and rapid antidepressant properties, yet its precise mechanism remains unclear.

Purpose of the Study:

• To elucidate the immune mechanisms underlying MDD.
• To investigate ketamine's antidepressant role through modulation of peripheral and central immune systems.
• To identify research gaps and propose future directions for novel antidepressant development.

Main Methods:

• Review of existing research on MDD pathophysiology and immune system involvement.
• Analysis of ketamine's immunomodulatory effects on peripheral inflammatory cytokines.
• Examination of ketamine's impact on central immune cells, including microglia and astrocytes.

Main Results:

• Ketamine exhibits both NMDAR antagonism and significant immunomodulatory effects.
• These immunomodulatory actions involve regulation of peripheral inflammatory cytokines and central glial cells (microglia, astrocytes).
• The interplay between immune dysregulation and MDD pathophysiology is highlighted.

Conclusions:

• Ketamine's antidepressant effects are likely mediated by its influence on both NMDAR pathways and immune system regulation.
• Targeting peripheral and central immune mechanisms presents a promising avenue for developing more effective antidepressants.
• Further research is needed to fully understand these complex interactions and optimize therapeutic strategies for MDD.